MARKET

BPTH

BPTH

Bio Path Hldg
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.57
-0.07
-0.92%
Closed 16:00 01/17 EST
OPEN
7.65
PREV CLOSE
7.64
HIGH
7.65
LOW
7.37
VOLUME
100.62K
TURNOVER
--
52 WEEK HIGH
73.52
52 WEEK LOW
1.610
MARKET CAP
21.83M
P/E (TTM)
-1.4165
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of BPTH and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

BPTH News

  • Bio-Path Holdings Provides Clinical Update and 2020 Business Outlook
  • GlobeNewswire.01/08 13:00
  • Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (Nasdaq: BPTH)
  • ACCESSWIRE.12/06/2019 14:25
  • UPDATE 2-Mexico's Televisa wins injunction on part of Disney-Fox deal; merger unaffected
  • Reuters.12/06/2019 03:03
  • Edited Transcript of BPTH earnings conference call or presentation 15-Nov-19 1:30pm GMT
  • Thomson Reuters StreetEvents.12/05/2019 21:42

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About BPTH

Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification. Its lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia, and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer.
More

Webull offers Bio-Path Holdings Inc (BPTH) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.